<DOC>
	<DOCNO>NCT02815280</DOCNO>
	<brief_summary>This Phase 3 study evaluate efficacy , safety long-term safety topical administration FMX-101 , 4 % minocycline foam treatment moderate-to-severe acne vulgaris .</brief_summary>
	<brief_title>A Study Compare Efficacy Safety Topical Administration FMX-101 Treatment Moderate-to-Severe Acne</brief_title>
	<detailed_description>This Phase 3 study evaluate efficacy , safety long-term safety topical administration FMX-101 , 4 % minocycline foam treatment moderate-to-severe acne vulgaris . The first 12 week study involves randomize , double-blind treatment active FMX-101 , 4 % matching vehicle . Subjects successfully complete 12-week double blind portion study offer opportunity continue trial additional 40 week ( total 1 year ) receive open-label treatment FMX-101 , 4 % .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Has facial acne vulgaris : 20 50 inflammatory lesion ( papule , pustule , nodule ) 25 100 noninflammatory lesion ( open close comedo ) No 2 nodule face IGA score moderate ( 3 ) severe ( 4 ) Willing use supply nonmedicated cleanser ( Cetaphil Gentle Skin Cleanser ) refrain use acne medication , medicate cleanser , excessive sun exposure , tan booth duration study Acne conglobata , acne fulminans , secondary acne ( chloracne , drug induce acne ) dermatological condition face facial hair ( eg , beard , sideburn , mustache ) could interfere clinical evaluation Sunburn face</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>acne</keyword>
</DOC>